Butterfly Medical Secures EU MDR Certification for Innovative BPH Treatment Device

In a landmark achievement, Butterfly Medical has announced that it has been awarded certification under the European Union Medical Device Regulation (EU MDR 2017/745) for its groundbreaking Prostatic Retraction Device. This development represents a significant step forward in the management of benign prostatic hyperplasia (BPH), a condition that affects millions of men worldwide.

Regulatory Milestone Achieved

The company's journey toward certification culminated after successfully completing a pivotal clinical trial with a cohort of 244 patients, followed by the submission of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA). Patrick MacCarthy, the CEO of Butterfly Medical, expressed his pride in achieving EU MDR certification, stating it underscores the firm’s dedication to rigorous clinical standards and quality assurance.

“Securing EU MDR certification is a major milestone for Butterfly Medical,” MacCarthy commented. “This achievement reflects years of clinical studies and quality system development, reinforcing our commitment to meeting stringent regulatory standards.”

Understanding the Device

The Butterfly Prostatic Retraction Device is ingeniously designed with anatomical considerations in mind. Its primary function is to alleviate urinary symptoms associated with BPH, while also serving as a less invasive alternative to more conventional treatments. Unlike traditional surgical methods, this unique device improves urinary flow without necessitating any cutting, burning, or removal of tissue. Furthermore, it operates without the need for special medical equipment, making it accessible to a broader range of healthcare facilities.

Dr. James C. Ulchaker, the Chief Medical Officer for Butterfly Medical, and an esteemed Emeritus Urologist at the Cleveland Clinic, emphasized the importance of providing varied treatment options. “BPH affects men differently, and patients deserve treatment solutions that cater to their specific needs and preferences, especially regarding the avoidance of tissue ablation or long-term pharmaceutical treatment,” he stated.

Looking Ahead

This certification not only enhances treatment options for BPH patients, but it also positions Butterfly Medical as a significant player in the medical device industry focused on addressing male health issues. The company is set to share further insights regarding its innovative treatments at the upcoming AdvaMed MedTech Conference on October 20, at the Thomas M. Menino Convention & Exhibition Center in Boston. Attendees can look forward to an informative session showcasing the latest advancements in BPH management.

About Butterfly Medical

Butterfly Medical is committed to transforming the landscape of benign prostatic hyperplasia treatments through its innovative minimally invasive solutions. With an aim to enhance the quality of life for those afflicted with BPH, the company’s flagship device presents itself as an alternative to both long-term medication and invasive surgical procedures. By doing so, Butterfly Medical seeks to expand treatment choices for millions of men, ensuring they have access to effective healthcare options tailored to their needs.

As the Butterfly Prostatic Retraction Device continues to gain traction in Europe, it is important to note that while the device has been CE Mark certified under EU regulations, it has yet to be approved by the FDA for commercial use in the United States. Potential risks associated with the Butterfly procedure may include urinary discomfort, urgency, frequency, bleeding, and in rare cases, the need for device removal.

For more detailed information, individuals can visit Butterfly Medical's website and stay connected through their LinkedIn profile for the latest updates and announcements.